Maraviroc (MVC)

DRUG3 trials

Sponsors

International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), HealthBio, Inc.

Conditions

HIV InfectionsLong COVID

Phase 2

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

Not yet recruitingNCT06974084

HealthBio, Inc.Long COVID

Start: 2026-07-15End: 2027-05-01Target: 252Updated: 2026-06-18

Phase 4

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

CompletedNCT02519777

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2016-04-21End: 2021-01-05Updated: 2022-04-22

Unknown Phase

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

CompletedNCT00977756

International Maternal Pediatric Adolescent AIDS Clinical Trials GroupHIV Infections

Start: 2002-08-31End: 2014-03-31Updated: 2015-08-07